Innovent reported RESTORE-3 success: what it means for Innovent stock

Published on 10/13/2026 at 04:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RESTORE-3 reached 60.40 percent versus 23.50 percent at Week 24. For Innovent stock, the China trial gap was 36.90 points.

Key points in brief

Innovent reported positive Phase 3 RESTORE-3 results for SYCUME in inactive thyroid eye disease on October 8, 2026.
The Week 24 proptosis response rate was 60.40 percent versus 23.50 percent for placebo.
Innovent had a market capitalization of HKD 156.1 billion as of October 13, 2026.
The company is scheduled to present additional clinical data at the 2026 ESMO meeting beginning October 23, 2026.

Innovent, KYG4818G1010, Illustration mit AI erstellt.

Innovent Biologics reported positive RESTORE-3 results on October 8, 2026, giving Innovent stock a clinical milestone to assess. According to PR Newswire, SYCUME met the primary endpoint in a Phase 3 trial for inactive thyroid eye disease, with a 60.40 percent response rate at Week 24.

Three milestones build the pipeline

On August 25, 2026, Innovent reported first-half revenue of CNY 8.62 billion, compared with CNY 5.95 billion a year earlier, according to The Wall Street Journal. That 45.04 percent increase provides the commercial backdrop for the companys expanding clinical pipeline.

On September 23, 2026, Futu reported that Innovent planned several presentations at the 2026 ESMO meeting, including Phase 3 data for IBI343 and additional studies of IBI363. On October 8, 2026, the company said RESTORE-3 enrolled 116 participants and produced a 36.90 percentage point treatment difference.

What does RESTORE-3 add?

The trial compared SYCUME with placebo in Chinese participants with inactive thyroid eye disease. The response rate was 60.40 percent for IBI311 versus 23.50 percent for placebo, while the least-squares mean change in proptosis was minus 1.88 millimeters versus minus 0.88 millimeters, according to PR Newswire. The 1.00 millimeter difference gives the headline response rate a second clinical measure.

For investors, the main commercial question is whether the new evidence can broaden SYCUMEs role beyond its existing use in thyroid eye disease. Innovent said follow-up is ongoing and complete data are planned for future conferences or peer-reviewed publication, leaving the trial at an evidence-building stage.

Next data arrive in October

Futu lists October 23, 2026, as the date for several ESMO presentations, with additional sessions scheduled for October 24 and October 25, 2026. The companys oncology data will therefore provide the next dated test of pipeline breadth.

Market value and investor context

Innovents market capitalization stood at HKD 156.1 billion as of October 13, 2026. The combination of CNY 8.62 billion in first-half revenue and the 60.40 percent RESTORE-3 response rate places commercial execution and clinical expansion at the center of the stock story. The further course of trading is shown by the continuously updated real-time quote of Innovent stock.